X
[{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Receives Formulation Patent Extending NCX 470 U.S","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Nicox SA"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Ocumension Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.3 million","newsHeadline":"Nicox to Receive \u20ac15 Million and Half of the Cost of the Second NCX 470 Phase 3 Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Nicox SA"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s Positive End-of-Phase 2 Meeting with the U.S. FDA Sets Stage for NCX 470 Phase 3 Program in Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Nicox SA"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Announces Plans for NCX 4251 Phase 2 Trial in Blepharitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Nicox SA"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Initiates Phase 2b Trial of NCX 4251, a Potential First-in-Class Treatment for Blepharitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Nicox SA"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s NCX 4251 Mississippi Phase 2b Blepharitis Trial Reaches 50% Enrollment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Nicox SA"},{"orgOrder":0,"company":"Nicox SA","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Nicox SA"},{"orgOrder":0,"company":"Eurobio Scientific","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eurobio Scientific Receives a $430,000 Milestone Payment From Allergan","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Eurobio Scientific"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europe","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Nicox SA"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s Positive Post Hoc Results from NCX 4251 Phase 2b Mississippi Trial Suggest Path Forward in Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Nicox SA"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s Positive FDA Meeting Shows Clear Path for NCX 4251 in Dry Eye","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Nicox SA"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Granted New Patent for NCX 4251 in Japan","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Nicox SA"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox at ARVO 2022: Presentation of Clinical Phase 2 results on NCX 4251 And New Non-clinical Evidence of Improved Hemodynamic and Retinal Cell Physiology on NCX 470","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Nicox SA"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
NCX 4251 is a novel and patented ophthalmic suspension of fluticasone propionate nanocrystals currently in Phase 2 development in the U.S. for patients with dry eye disease.
Lead Product(s):
Fluticasone Propionate
Therapeutic Area: Ophthalmology
Product Name: NCX 4251
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 02, 2022
Details:
Newly granted patent extends the coverage for NCX 4251 in Japan to 2040 and, it covers ophthalmic suspensions comprising a specific form of fluticasone propionate nanocrystals and the method for manufacturing the ophthalmic suspensions.
Lead Product(s):
Fluticasone Propionate
Therapeutic Area: Ophthalmology
Product Name: NCX 4251
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 22, 2022
Details:
Fluticasone propionate, the active ingredient in NCX 4251, is a well-established corticosteroid which has been marketed for more than 20 years for a number of non-ophthalmic indications, including asthma and allergic rhinitis.
Lead Product(s):
Fluticasone Propionate
Therapeutic Area: Ophthalmology
Product Name: NCX 4251
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 08, 2022
Details:
NCX 4251, ophthalmic suspension of fluticasone propionate nanocrystals for the topical treatment of the eyelids in patients with acute exacerbations of blepharitis, showed statistically significant improvement or reduction in the dry eye symptoms.
Lead Product(s):
Fluticasone Propionate
Therapeutic Area: Ophthalmology
Product Name: NCX 4251
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 30, 2021
Details:
NCX 4251, has been issued by EPO, and its patent coverage is extended in the EU to 2040.The patent covers ophthalmic suspensions comprising a specific form of fluticasone propionate nanocrystals and the method for manufacturing the ophthalmic suspensions.
Lead Product(s):
Fluticasone Propionate
Therapeutic Area: Ophthalmology
Product Name: NCX 4251
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 17, 2021
Details:
During the clinical development of AGN-231868, Eurobio Scientific remains eligible to other milestone payments linked to successful transitions to further clinical stages.
Lead Product(s):
AGN-231868
Therapeutic Area: Ophthalmology
Product Name: AGN-231868
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Allergan Aesthetics
Deal Size: $5.0 million
Upfront Cash: Undisclosed
Deal Type: Collaboration
October 06, 2021
Details:
Mississippi is a Phase 2b clinical trial of NCX 4251, evaluating once-daily dosed NCX 4251 0.1% versus placebo in patients with acute exacerbations of blepharitis.
Lead Product(s):
Fluticasone Propionate
Therapeutic Area: Ophthalmology
Product Name: NCX 4251
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
OcuMension Therapeutics
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 01, 2021
Details:
Mississippi is a Phase 2b clinical trial of NCX 4251, evaluating once-daily dosed NCX 4251 0.1% versus placebo in patients with acute exacerbations of blepharitis. It is expected to randomize 200 patients at clinical sites across the U.S.
Lead Product(s):
Fluticasone Propionate
Therapeutic Area: Ophthalmology
Product Name: NCX 4251
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 23, 2021
Details:
NCX 4251 has first-in-class potential, addressing the unmet medical need of patients with blepharitis. Mississippi Phase 2b trial will evaluate once-daily dosed NCX 4251 0.1% versus placebo in patients with acute exacerbations of blepharitis.
Lead Product(s):
Fluticasone Propionate
Therapeutic Area: Ophthalmology
Product Name: NCX 4251
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 15, 2020
Details:
NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals, was evaluated in the successful Danube Phase 2 trial completed in late 2019.
Lead Product(s):
Fluticasone Propionate
Therapeutic Area: Ophthalmology
Product Name: NCX 4251
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 13, 2020